{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:29Z","timestamp":1783329329430,"version":"3.54.6"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013414","name":"Conseil R\u00e9gional des Pays de la Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008280","name":"Universite Angers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012948","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur, de la Recherche et de l'Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011045","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004562","name":"Minist\u00e8re de l'Enseignement sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-19-ENM3-0003-01"],"award-info":[{"award-number":["ANR-19-ENM3-0003-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-18- 01"],"award-info":[{"award-number":["ANR-11-LABX-18- 01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201213","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:16:46Z","timestamp":1776874606000},"page":"201213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7940-1855","authenticated-orcid":false,"given":"Ma\u00ebl","family":"Bouillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Lapoujade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00ebtitia","family":"Basset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Hollenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Garcion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201213_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41392-025-02161-7","article-title":"Oncogenic gene fusions in cancer: from biology to therapy","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2026.201213_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12272-020-01232-3","article-title":"Small molecule tyrosine kinase inhibitors in glioblastoma","volume":"43","author":"Kim","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.omton.2026.201213_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201213_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201213_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10014-010-0275-7","article-title":"Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging","volume":"27","author":"Yamahara","year":"2010","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.omton.2026.201213_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201213_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1586\/14737140.2013.840090","article-title":"The role of Gliadel wafers in the treatment of high-grade gliomas","volume":"13","author":"Bregy","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.omton.2026.201213_bib10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-025-57263-1","article-title":"Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial","volume":"16","author":"Brenner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201213_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMe2401307","article-title":"CAR T-Cell Therapy for Glioblastoma","volume":"390","author":"Jenkins","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201213_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/biomedicines12010238","article-title":"CRISPR\/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review","volume":"12","author":"Begagi\u0107","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201213_bib13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/brainsci13111602","article-title":"Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings","volume":"13","author":"Begagi\u0107","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.omton.2026.201213_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201213_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41568-024-00769-5","article-title":"Chromothripsis in cancer","volume":"25","author":"Simovic-Lorenz","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib16","article-title":"Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma","volume":"4","author":"Grogan","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201213_bib17","article-title":"Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion","volume":"6","author":"Cerretti","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201213_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.715206","article-title":"Fusion Genes Altered in Adult Malignant Gliomas","volume":"12","author":"You","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omton.2026.201213_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gcc.10207","article-title":"Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)","volume":"37","author":"Charest","year":"2003","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201213_bib21","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, Characterization, and Inhibition of FGFR\u2013TACC Fusions in IDH Wild-type Glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib22","article-title":"Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications","volume":"8","author":"Aulakh","year":"2026","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201213_bib23","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-21-3521","article-title":"ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma","volume":"29","author":"Blandin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib24","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.3390\/cancers13225799","article-title":"Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?","volume":"13","author":"Aldaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201213_bib25","article-title":"Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2003.07.006","article-title":"Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (\u2018Iressa\u2019)","volume":"202","author":"Stea","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201213_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","article-title":"Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells","volume":"38","author":"Vengoji","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib28","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-019-1235-7","article-title":"The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma","volume":"38","author":"Liu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/gcc.23143","article-title":"Glioblastoma with novel EGFR mutations ( T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report","volume":"62","author":"Boongird","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib31","first-page":"3327","article-title":"Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.omton.2026.201213_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201213_bib33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2026.201213_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123994","article-title":"Polymer-lipid hybrid nanomedicines to deliver siRNA in and against glioblastoma cells","volume":"654","author":"Rinaldi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omton.2026.201213_bib37","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201213_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201213_bib39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201213_bib40","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1039\/D4CS00799A","article-title":"Natural, modified and conjugated carbohydrates in nucleic acids","volume":"54","author":"Dhara","year":"2025","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.omton.2026.201213_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102437","article-title":"Development, opportunities, and challenges of siRNA nucleic acid drugs","volume":"36","author":"Xiao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib42","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/acs.jmedchem.9b01839","article-title":"Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development","volume":"63","author":"Humphreys","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201213_bib43","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41594-020-0495-4","article-title":"Ribosomes clear the way for siRNA targeting","volume":"27","author":"Ma\u0142ecka","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omton.2026.201213_bib44","doi-asserted-by":"crossref","first-page":"E6597","DOI":"10.1073\/pnas.1517039112","article-title":"Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence","volume":"112","author":"Gavrilov","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201213_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117825","article-title":"Advances in structural-guided modifications of siRNA","volume":"110","author":"Li","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.omton.2026.201213_bib46","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1021\/acs.jmedchem.4c02250","article-title":"Expanding Conjugate Space of RNAi Therapeutics: Ligand at the 3\u2032 End of the Antisense Strand Achieves Uncompromised In Vivo Potency and Efficacy and Reveals Interactions with the Argonaute-2 PAZ Domain","volume":"68","author":"Das","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201213_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102415","article-title":"Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions","volume":"36","author":"Kliuchnikov","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1261\/rna.073783.119","article-title":"siRNA potency enhancement via chemical modifications of nucleotide bases at the 5\u2032-end of the siRNA guide strand","volume":"27","author":"Shinohara","year":"2021","journal-title":"RNA"},{"key":"10.1016\/j.omton.2026.201213_bib49","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/nat.2021.0068","article-title":"Elimination of Off-Target Effect by Chemical Modification of 5\u2032-End of siRNA","volume":"32","author":"Shiohama","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omton.2026.201213_bib50","article-title":"RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine","volume":"2","author":"Parker Kerrigan","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201213_bib51","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omton.2026.201213_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78337-y","article-title":"Discovery of miRNA\u2013mRNA regulatory networks in glioblastoma reveals novel insights into tumor microenvironment remodeling","volume":"14","author":"Grigore","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201213_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175388","article-title":"MicroRNA-based therapy for glioblastoma: Opportunities and challenges","volume":"938","author":"Lei","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omton.2026.201213_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215811","article-title":"Therapeutic targeting of RBPJ, an upstream regulator of ETV6 gene, abrogates ETV6-NTRK3 fusion gene transformations in glioblastoma","volume":"544","author":"Biswas","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2026.201213_bib55","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/cells12202467","article-title":"Exploring the Relationship between Fusion Genes and MicroRNAs in Cancer","volume":"12","author":"Panicker","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201213_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10147-020-01685-y","article-title":"Recent advances of the regulation roles of MicroRNA in glioblastoma","volume":"25","author":"Yan","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"10.1016\/j.omton.2026.201213_bib58","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/hum.2024.113","article-title":"Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies","volume":"35","author":"Brillante","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201213_bib59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201213_bib60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","article-title":"Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes","volume":"317","author":"Kim","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omton.2026.201213_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121036","article-title":"Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy","volume":"276","author":"Liu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.omton.2026.201213_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/1061186X.2016.1207648","article-title":"Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model","volume":"25","author":"Oh","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.omton.2026.201213_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13046-024-03058-z","article-title":"LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B","volume":"43","author":"Dong","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-024-03000-3","article-title":"TGF-\u03b2-activated circRYK drives glioblastoma progression by increasing VLDLR mRNA expression and stability in a ceRNA- and RBP-dependent manner","volume":"43","author":"Wang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib65","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ncrna.2023.12.005","article-title":"Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast cancer","volume":"9","author":"Zhu","year":"2024","journal-title":"Noncoding. RNA Res."},{"key":"10.1016\/j.omton.2026.201213_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12920-024-01851-5","article-title":"Long noncoding RNA UNC5B-AS1 suppresses cell proliferation by sponging miR-24-3p in glioblastoma multiforme","volume":"17","author":"Song","year":"2024","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.omton.2026.201213_bib67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.omtn.2023.04.001","article-title":"Synthetic miR-21 decoy circularized by tRNA splicing mechanism inhibited tumorigenesis in glioblastoma in vitro and in vivo models","volume":"32","author":"Bayat","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib68","article-title":"Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN\/MADD domain containing 2D","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201213_bib69","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/nar\/gkae141","article-title":"Chemical modification patterns for microRNA therapeutic mimics: a structure-activity relationship (SAR) case-study on miR-200c","volume":"52","author":"Garreau","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201213_bib70","doi-asserted-by":"crossref","first-page":"2843990","DOI":"10.1155\/2022\/2843990","article-title":"MicroRNA-147a Targets SLC40A1 to Induce Ferroptosis in Human Glioblastoma","volume":"2022","author":"Xu","year":"2022","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.omton.2026.201213_bib71","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201213_bib72","doi-asserted-by":"crossref","first-page":"14475","DOI":"10.3390\/ijms150814475","article-title":"MicroRNAs, genomic instability and cancer","volume":"15","author":"Vincent","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201213_bib73","first-page":"855","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201213_bib74","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41467-017-01176-1","article-title":"Frequent miRNA-convergent fusion gene events in breast cancer","volume":"8","author":"Persson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201213_bib75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-021-00204-7","article-title":"MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3\u2032UTR","volume":"10","author":"Johnson","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.omton.2026.201213_bib77","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3390\/cancers16172940","article-title":"Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside","volume":"16","author":"\u00c7akan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201213_bib78","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1039\/D4MD00394B","article-title":"The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy","volume":"15","author":"Blitek","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.omton.2026.201213_bib79","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201213_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31636-2","article-title":"An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides","volume":"13","author":"Baker","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201213_bib81","doi-asserted-by":"crossref","first-page":"29773","DOI":"10.1021\/jacs.4c11402","article-title":"Synthesis, Biophysical and Biological Evaluation of Splice-Switching Oligonucleotides with Multiple LNA-Phosphothiotriester Backbones","volume":"146","author":"Dhara","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omton.2026.201213_bib82","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1021\/acs.accounts.0c00078","article-title":"DNA Analogues Modified at the Nonlinking Positions of Phosphorus","volume":"53","author":"Kumar","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omton.2026.201213_bib83","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1093\/nar\/gkad716","article-title":"Stability and mechanism of threose nucleic acid toward acid-mediated degradation","volume":"51","author":"Lee","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201213_bib84","first-page":"10310","article-title":"2\u2032\u03b2-Fluoro-Tricyclo Nucleic Acids (2\u2032F-tc-ANA): Thermal Duplex Stability, Structural Studies, and RNase H Activation","volume":"23","author":"Istrate","year":"2017","journal-title":"Chemistry (Easton)."},{"key":"10.1016\/j.omton.2026.201213_bib85","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201213_bib86","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201213_bib87","article-title":"Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine","volume":"11","author":"Rehman","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.omton.2026.201213_bib88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-1-4939-8651-4_26","article-title":"Pre-mRNA Splicing Modulation by Antisense Oligonucleotides","volume":"1828","author":"Singh","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2026.201213_bib89","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/cancers16101944","article-title":"Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma","volume":"16","author":"Desgraves","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201213_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201213_bib91","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-3024","article-title":"Therapeutic Targeting of TGF\u03b2 Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas","volume":"25","author":"Papachristodoulou","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201213_bib92","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.omtn.2018.04.004","article-title":"Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells","volume":"11","author":"Arnold","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib93","first-page":"118","article-title":"Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels","volume":"9","author":"Smetsers","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201213_bib94","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s10637-019-00862-9","article-title":"Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells","volume":"38","author":"Hoshiko","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.omton.2026.201213_bib95","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/cancers15123127","article-title":"Reduction of Tumor Growth with RNA-Targeting Treatment of the NAB2-STAT6 Fusion Transcript in Solitary Fibrous Tumor Models","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201213_bib96","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/bab.2244","article-title":"SELEX: Critical factors and optimization strategies for successful aptamer selection","volume":"69","author":"Kohlberger","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.omton.2026.201213_bib97","doi-asserted-by":"crossref","first-page":"e1543","DOI":"10.1002\/wnan.1543","article-title":"Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles","volume":"11","author":"Sivakumar","year":"2019","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.omton.2026.201213_bib98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","article-title":"Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer","volume":"86","author":"Bates","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.omton.2026.201213_bib99","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2013.300","article-title":"Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFR\u03b2 Aptamer","volume":"22","author":"Camorani","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201213_bib100","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1021\/jacs.3c00841","article-title":"Aptamer-Based Targeted Delivery of Functional Nucleic Acids","volume":"145","author":"Xie","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omton.2026.201213_bib101","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jacs.1c09574","article-title":"Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy","volume":"144","author":"Zhu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omton.2026.201213_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124173","article-title":"Advances in aptamer-mediated targeted delivery system for cancer treatment","volume":"238","author":"He","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.omton.2026.201213_bib103","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nbt1223","article-title":"Cell type\u2013specific delivery of siRNAs with aptamer-siRNA chimeras","volume":"24","author":"McNamara","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201213_bib104","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcis.2016.12.004","article-title":"Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-\u03b3-glutamylglutamine)\u2013paclitaxel nanoconjugates","volume":"490","author":"Luo","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.omton.2026.201213_bib106","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.omtn.2018.01.001","article-title":"Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells","volume":"10","author":"Zhang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omton.2026.201213_bib107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/acs.langmuir.1c02500","article-title":"Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy","volume":"38","author":"Liang","year":"2022","journal-title":"Langmuir"},{"key":"10.1016\/j.omton.2026.201213_bib108","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1002\/1873-3468.13914","article-title":"A G-quadruplex-forming RNA aptamer binds to the MTG8 TAFH domain and dissociates the leukemic AML1-MTG8 fusion protein from DNA","volume":"594","author":"Fukunaga","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omton.2026.201213_bib109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/neuonc\/noad156","article-title":"Aptamers in neuro-oncology: An emerging therapeutic modality","volume":"26","author":"Doherty","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115657","article-title":"Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives","volume":"224","author":"Parvar","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omton.2026.201213_bib111","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood\u2013brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201213_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr9266","article-title":"Bioengineered protein nanocarrier facilitating siRNA escape from lysosomes for targeted RNAi therapy in glioblastoma","volume":"11","author":"Jin","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201213_bib113","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/rna.20206","article-title":"RNA mediated toll-like receptor stimulation in health and disease","volume":"9","author":"Dalpke","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.omton.2026.201213_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201213_bib115","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:21:43Z","timestamp":1783326103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000895"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201213","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201213"}}